1,100,473 Shares in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Bought by AWM Investment Company Inc.

AWM Investment Company Inc. acquired a new stake in shares of Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 1,100,473 shares of the company's stock, valued at approximately $4,534,000. AWM Investment Company Inc. owned about 1.84% of Eledon Pharmaceuticals as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. RA Capital Management L.P. acquired a new stake in shares of Eledon Pharmaceuticals during the 4th quarter valued at about $14,693,000. Sphera Funds Management LTD. lifted its stake in Eledon Pharmaceuticals by 96.7% in the 4th quarter. Sphera Funds Management LTD. now owns 2,551,619 shares of the company's stock worth $10,513,000 after purchasing an additional 1,254,298 shares in the last quarter. First Light Asset Management LLC purchased a new position in Eledon Pharmaceuticals in the 4th quarter worth approximately $9,595,000. Blue Owl Capital Holdings LP purchased a new position in Eledon Pharmaceuticals in the 4th quarter worth approximately $8,075,000. Finally, Woodline Partners LP lifted its stake in Eledon Pharmaceuticals by 98.3% in the 4th quarter. Woodline Partners LP now owns 1,671,822 shares of the company's stock worth $6,888,000 after purchasing an additional 828,930 shares in the last quarter. Hedge funds and other institutional investors own 56.77% of the company's stock.

Eledon Pharmaceuticals Trading Up 1.0%

Shares of ELDN stock traded up $0.03 on Friday, reaching $3.05. 175,430 shares of the stock were exchanged, compared to its average volume of 272,701. The business's 50 day moving average price is $3.12 and its 200 day moving average price is $3.89. The company has a market capitalization of $182.64 million, a price-to-earnings ratio of -1.52 and a beta of 0.08. Eledon Pharmaceuticals, Inc. has a twelve month low of $2.30 and a twelve month high of $5.54.

Eledon Pharmaceuticals (NASDAQ:ELDN - Get Free Report) last issued its earnings results on Wednesday, May 14th. The company reported ($0.08) EPS for the quarter, topping analysts' consensus estimates of ($0.28) by $0.20. Equities research analysts forecast that Eledon Pharmaceuticals, Inc. will post -0.81 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have recently commented on ELDN. Wall Street Zen raised shares of Eledon Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research report on Thursday. Guggenheim initiated coverage on shares of Eledon Pharmaceuticals in a research note on Tuesday, January 28th. They issued a "buy" rating and a $9.00 price target for the company.

Eledon Pharmaceuticals Company Profile

Eledon Pharmaceuticals, Inc operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).